Researchers developed a biochemical platform that would enable them high-resolution view of family of enzymes for finding better cure for cancer.
Researchers observed the mechanism of an enzymes, called lysine methyltransferases, and the mannerism in which it marks protein that leads to change its function. These findings might aid in developing a number of therapeutic medicines according to the researchers. The findings were published in the journal Science Advances on November 28, 2018.
The platform was developed by Van Andel Research Institute's Scott Rothbart, Ph.D., in collaboration with EpiCypher, Inc. The lesser-known enzyme family could be determined using the new technology. Scott Rothbart says, â€œSeveral inhibitors of these enzymes are currently in the clinical development pipeline for cancer therapy. Defining the spectrum of their activity is critical for understanding exactly how these drugs work and for selecting reliable biomarkers to track their activity in patients.â€
This new technology helps researchers to tag large number of proteins by lysine methylation than previously thought.
Evan Cornett, Ph.D., postdoctoral fellow at the Van Andel Research Institute and first author of the study, said, â€œOur study suggests that what we currently know about lysine methylation is just the tip of the iceberg. The method we developed will allow us to identify new targets across the full set of lysine methyltransferases in humans and, in doing so, help us and others determine which cancers and other diseases could benefit from treatments targeting this class of enzymes.â€
This technology could be easily used for identifying a number of therapeutic ailments and optimal target substrates for high-throughput inhibitor screening.
Subscribe to our newsletter to get notification about new updates,information, discount, etc..